AU2018319594B2 - Liposomal formulation for joint lubrication - Google Patents

Liposomal formulation for joint lubrication Download PDF

Info

Publication number
AU2018319594B2
AU2018319594B2 AU2018319594A AU2018319594A AU2018319594B2 AU 2018319594 B2 AU2018319594 B2 AU 2018319594B2 AU 2018319594 A AU2018319594 A AU 2018319594A AU 2018319594 A AU2018319594 A AU 2018319594A AU 2018319594 B2 AU2018319594 B2 AU 2018319594B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
liposomes
dmpc
mannitol
joint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018319594A
Other languages
English (en)
Other versions
AU2018319594A1 (en
Inventor
Maty Ayal-Hershkovitz
Yechezkel Barenholz
Yaniv DOLEV
Gadi Sarfati
Keren TURJEMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moebius Medical Ltd
Original Assignee
Moebius Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moebius Medical Ltd filed Critical Moebius Medical Ltd
Publication of AU2018319594A1 publication Critical patent/AU2018319594A1/en
Priority to AU2023203309A priority Critical patent/AU2023203309B2/en
Application granted granted Critical
Publication of AU2018319594B2 publication Critical patent/AU2018319594B2/en
Priority to AU2025200077A priority patent/AU2025200077A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/10—Materials for lubricating medical devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018319594A 2017-08-22 2018-08-21 Liposomal formulation for joint lubrication Active AU2018319594B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023203309A AU2023203309B2 (en) 2017-08-22 2023-05-26 Liposomal formulation for joint lubrication
AU2025200077A AU2025200077A1 (en) 2017-08-22 2025-01-07 Liposomal formulation for joint lubrication

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548429P 2017-08-22 2017-08-22
US62/548,429 2017-08-22
PCT/IL2018/050923 WO2019038763A1 (en) 2017-08-22 2018-08-21 LIPOSOMAL FORMULATION FOR JOINT LUBRICATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023203309A Division AU2023203309B2 (en) 2017-08-22 2023-05-26 Liposomal formulation for joint lubrication

Publications (2)

Publication Number Publication Date
AU2018319594A1 AU2018319594A1 (en) 2020-02-20
AU2018319594B2 true AU2018319594B2 (en) 2023-06-15

Family

ID=65439381

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018319594A Active AU2018319594B2 (en) 2017-08-22 2018-08-21 Liposomal formulation for joint lubrication
AU2023203309A Active AU2023203309B2 (en) 2017-08-22 2023-05-26 Liposomal formulation for joint lubrication
AU2025200077A Pending AU2025200077A1 (en) 2017-08-22 2025-01-07 Liposomal formulation for joint lubrication

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023203309A Active AU2023203309B2 (en) 2017-08-22 2023-05-26 Liposomal formulation for joint lubrication
AU2025200077A Pending AU2025200077A1 (en) 2017-08-22 2025-01-07 Liposomal formulation for joint lubrication

Country Status (25)

Country Link
US (3) US11123293B2 (enExample)
EP (2) EP4223284A1 (enExample)
JP (2) JP7082336B2 (enExample)
KR (2) KR102607729B1 (enExample)
CN (2) CN114601799B (enExample)
AU (3) AU2018319594B2 (enExample)
BR (1) BR112020003767B1 (enExample)
CA (2) CA3073368C (enExample)
DK (1) DK3672653T3 (enExample)
EA (1) EA202090476A1 (enExample)
ES (1) ES2948715T3 (enExample)
FI (1) FI3672653T3 (enExample)
HR (1) HRP20230566T1 (enExample)
HU (1) HUE062030T2 (enExample)
IL (3) IL272630B2 (enExample)
LT (1) LT3672653T (enExample)
MA (1) MA49959B1 (enExample)
MX (2) MX2020002041A (enExample)
MY (1) MY197149A (enExample)
PH (1) PH12020500331A1 (enExample)
PL (1) PL3672653T3 (enExample)
PT (1) PT3672653T (enExample)
SG (1) SG11202000773QA (enExample)
SI (1) SI3672653T1 (enExample)
WO (1) WO2019038763A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782181B (zh) * 2019-02-11 2022-11-01 以色列商莫比斯醫療有限公司 用於關節潤滑的脂質體調配物
JP2021013788A (ja) * 2020-11-10 2021-02-12 株式会社三洋物産 遊技機
CN118678947A (zh) * 2022-01-02 2024-09-20 莫比斯医疗有限公司 脂质体捕集体积的测定
CN119816311A (zh) 2023-01-19 2025-04-11 莫比斯医疗有限公司 一种治疗关节障碍中的疼痛的长效脂质体组合物
KR20250018222A (ko) * 2023-07-26 2025-02-05 차의과학대학교 산학협력단 미토콘드리아가 캡슐화된 세포막 융합유도 리포좀을 포함하는 골관절염 치료를 위한 약학 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078445A1 (en) * 2001-03-29 2002-10-10 The Scripps Research Institute Formulations comprising entrapped active ingredients and uses thereof
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
WO2004047792A2 (de) * 2002-11-24 2004-06-10 Novosom Ag Liposomale glucocorticoide
WO2008038292A2 (en) * 2006-09-28 2008-04-03 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
US20090232883A1 (en) * 2006-07-03 2009-09-17 Terumo Kabushiki Kaisha Method of separating vesicle, process for producing medicinal preparation, and method of evaluation
WO2013153221A1 (en) * 2012-04-12 2013-10-17 Sequessome Technology Holdings Limited Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
CN105377238A (zh) * 2012-07-05 2016-03-02 台湾微脂体股份有限公司 治疗关节炎的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5403592A (en) 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
EP0319638A1 (en) * 1987-12-08 1989-06-14 Estee Lauder Inc. Liposome containing cosmetic and pharmaceutical compositions and methods for utilizing such compositions
US5941909A (en) * 1995-02-14 1999-08-24 Mentor Corporation Filling material for soft tissue implant prostheses and implants made therewith
AUPN723395A0 (en) 1995-12-19 1996-01-18 Macnaught Medical Pty Limited Lubrication methods
US6379648B1 (en) * 1999-02-01 2002-04-30 The Curators Of The University Of Missouri Biodegradable glass compositions and methods for radiation therapy
US6800298B1 (en) * 2000-05-11 2004-10-05 Clemson University Biological lubricant composition and method of applying lubricant composition
US20040047807A1 (en) * 2001-01-24 2004-03-11 Dominik Meyer Use of neurotoxic substances in producing a medicament for treating joint pains
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
EP1423081A4 (en) 2001-06-25 2005-05-25 Depuy Int Ltd COMPOSITION WITH GLYCOSAMINOGYCANES AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC JOINTS
IL159334A0 (en) * 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
US7205006B2 (en) 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
US7749485B2 (en) 2004-06-03 2010-07-06 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
CN101027065A (zh) * 2004-06-15 2007-08-29 陈献 磷脂组合物及其制备和使用方法
US20070071840A1 (en) 2005-09-27 2007-03-29 Sridevi Dhanaraj Method for treatment of cartilage disorders with centella extract
ITPD20060202A1 (it) 2006-05-22 2007-11-23 Univ Degli Studi Trieste Miscele polimeriche di polisaccaridi anionici e cationici e loro impiego
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
US8834920B2 (en) 2006-12-21 2014-09-16 Alza Corporation Liposome composition for targeting egfr receptor
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
US20110171288A1 (en) 2008-02-20 2011-07-14 Fatemeh Mohammadi Topical compositions and methods for whitening skin
BR112012032153A2 (pt) 2010-06-17 2017-08-08 Yeda Res And Development Company Ltd método para a lubrificação de uma ou mais superfícies não biológicas, método para a lubrificação de uma ou mais superfícies de um tecido biológico em um indivíduo mamífero, uso de lipossomas na fase em gel e lipossoma misto
IL206739A (en) * 2010-06-30 2016-06-30 David Segal An injectable drug containing silitol as an active substance
US20140038917A1 (en) 2011-04-19 2014-02-06 Anteis S.A. Sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
CN104688721A (zh) 2014-10-11 2015-06-10 黄萍 一种含紫杉醇脂质体的抗类风湿性关节炎药物凝胶剂及其制备方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078445A1 (en) * 2001-03-29 2002-10-10 The Scripps Research Institute Formulations comprising entrapped active ingredients and uses thereof
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
WO2004047792A2 (de) * 2002-11-24 2004-06-10 Novosom Ag Liposomale glucocorticoide
US20090232883A1 (en) * 2006-07-03 2009-09-17 Terumo Kabushiki Kaisha Method of separating vesicle, process for producing medicinal preparation, and method of evaluation
WO2008038292A2 (en) * 2006-09-28 2008-04-03 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
WO2013153221A1 (en) * 2012-04-12 2013-10-17 Sequessome Technology Holdings Limited Vesicular formulations for use in the treatment of pain or reduced mobility of a joint
CN105377238A (zh) * 2012-07-05 2016-03-02 台湾微脂体股份有限公司 治疗关节炎的方法

Also Published As

Publication number Publication date
IL272630B2 (en) 2023-09-01
JP7383759B2 (ja) 2023-11-20
CN111065423B (zh) 2022-04-12
BR112020003767B1 (pt) 2023-10-10
CA3219776A1 (en) 2019-02-28
JP2022110090A (ja) 2022-07-28
KR102808544B1 (ko) 2025-05-19
US20200170948A1 (en) 2020-06-04
MY197149A (en) 2023-05-26
ES2948715T3 (es) 2023-09-18
EP3672653A4 (en) 2021-01-13
IL301801A (en) 2023-05-01
HRP20230566T1 (hr) 2023-08-18
US20210369613A1 (en) 2021-12-02
IL301801B1 (en) 2024-06-01
IL272630A (en) 2020-03-31
US20250114304A1 (en) 2025-04-10
HUE062030T2 (hu) 2023-09-28
WO2019038763A1 (en) 2019-02-28
PL3672653T3 (pl) 2023-08-14
PH12020500331A1 (en) 2020-10-05
EA202090476A1 (ru) 2020-06-29
LT3672653T (lt) 2023-07-10
IL272630B1 (en) 2023-05-01
IL312816A (en) 2024-07-01
CN111065423A (zh) 2020-04-24
BR112020003767A2 (pt) 2020-09-01
AU2023203309B2 (en) 2024-10-10
IL301801B2 (en) 2024-10-01
CA3073368A1 (en) 2019-02-28
US11123293B2 (en) 2021-09-21
SI3672653T1 (sl) 2023-08-31
MX2023009082A (es) 2023-08-08
SG11202000773QA (en) 2020-03-30
US12214077B2 (en) 2025-02-04
EP3672653B1 (en) 2023-03-29
AU2018319594A1 (en) 2020-02-20
MA49959A (fr) 2020-07-01
MX2020002041A (es) 2020-08-13
MA49959B1 (fr) 2023-07-31
CA3073368C (en) 2024-01-02
KR20200044006A (ko) 2020-04-28
DK3672653T3 (da) 2023-06-12
EP3672653A1 (en) 2020-07-01
KR20230166148A (ko) 2023-12-06
CN114601799A (zh) 2022-06-10
AU2025200077A1 (en) 2025-01-23
NZ761298A (en) 2024-03-22
JP7082336B2 (ja) 2022-06-08
EP4223284A1 (en) 2023-08-09
CN114601799B (zh) 2023-09-26
JP2020531538A (ja) 2020-11-05
AU2023203309A1 (en) 2023-06-22
PT3672653T (pt) 2023-06-29
KR102607729B1 (ko) 2023-11-29
FI3672653T3 (fi) 2023-06-07

Similar Documents

Publication Publication Date Title
AU2023203309B2 (en) Liposomal formulation for joint lubrication
US8895054B2 (en) Methods for joint lubrication and cartilage wear prevention making use of glycerophospholipids
TWI782181B (zh) 用於關節潤滑的脂質體調配物
HK40030411A (en) Liposomal formulation for joint lubrication
HK40030411B (en) Liposomal formulation for joint lubrication
EA042384B1 (ru) Липосомальный состав для обеспечения смазывающей среды сустава
BR122022020806B1 (pt) Composição farmacêutica que compreende lipossomas, processo para a preparação da mesma e usos da dita composição para lubrificar uma articulação e tratar dor ou irritação em uma articulação

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)